Stay updated on ACP-196/Pembrolizumab in Urothelial Bladder Cancer Clinical Trial
Sign up to get notified when there's something new on the ACP-196/Pembrolizumab in Urothelial Bladder Cancer Clinical Trial page.

Latest updates to the ACP-196/Pembrolizumab in Urothelial Bladder Cancer Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoNo Change Detected
- Check16 days agoChange Detected- Removed version v3.1.0 and added notice about government funding lapse and current NIH Clinical Center status with links, plus new version tag v3.2.0. The page now communicates operating status details and a newer software version.SummaryDifference6%
- Check23 days agoChange DetectedChanged the revision from v3.0.2 to v3.1.0, indicating a minor version update with no other content changes.SummaryDifference0.1%
- Check38 days agoChange DetectedVersion updated from v3.0.1 to v3.0.2; 'Back to Top' removed as a minor UI change. No changes to core content, pricing, stock, or proper nouns.SummaryDifference0.3%
- Check45 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes to core content, names, pricing, or availability.SummaryDifference0.4%
- Check52 days agoChange DetectedThe web page has undergone significant changes, including the addition of a facility name and location, as well as updated drug information for Pembrolizumab and Acalabrutinib. However, many details regarding locations and drug classifications have been removed.SummaryDifference6%
- Check66 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.1%
Stay in the know with updates to ACP-196/Pembrolizumab in Urothelial Bladder Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ACP-196/Pembrolizumab in Urothelial Bladder Cancer Clinical Trial page.